Alzheimer's - Dementia, Author Interviews, Lipids, Vanderbilt / 18.01.2026
Vanderbilt Study Provides Most Definitive Evidence To Date that APOE Contributes to SuperAging
MedicalResearch.com Interview with:
[caption id="attachment_72035" align="alignleft" width="200"]
Dr. Gaynor[/caption]
Leslie S. Gaynor, PhD
Clinical Neuropsychologist & Assistant Professor of Medicine
Division of Geriatric Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, TN 37203
MedicalResearch.com: What is the background for this study?
Response: The US population is rapidly aging, and the oldest members of our population are also the most vulnerable to developing clinical dementia. We are interested in studying older adults ages 80+ who display cognitive resilience despite this increased risk of dementia and actually display exceptional memory performance compared to their same-aged, typically performing peers. These “SuperAgers,”—i.e., 80+-year-old adults with memory performance that is comparable to or surpasses that of adults 20 to 30 years their junior—may hold the key to uncovering genetic factors that predict exceptionally healthy longevity.
Dr. Gaynor[/caption]
Leslie S. Gaynor, PhD
Clinical Neuropsychologist & Assistant Professor of Medicine
Division of Geriatric Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, TN 37203
MedicalResearch.com: What is the background for this study?
Response: The US population is rapidly aging, and the oldest members of our population are also the most vulnerable to developing clinical dementia. We are interested in studying older adults ages 80+ who display cognitive resilience despite this increased risk of dementia and actually display exceptional memory performance compared to their same-aged, typically performing peers. These “SuperAgers,”—i.e., 80+-year-old adults with memory performance that is comparable to or surpasses that of adults 20 to 30 years their junior—may hold the key to uncovering genetic factors that predict exceptionally healthy longevity.
Dr. Thorne[/caption]
Sally Thorne RN, PhD, FAAN, FCAHS, FCAN, CM
Professor Emeritus, School of Nursing
Co-Principal Investigator with :
[caption id="attachment_71969" align="alignleft" width="133"]
Dr. Pesut[/caption]
Dr. Barbara Pesut PhD, RN
Professor in the School of Nursing
Principal Research Chair in Palliative and End of Life Care
University of British Columbia
MedicalResearch.com: What is the background for this study?
Response: Medical assistance in dying (MAiD) was legalized in Canada in June of 2016 for Canadians who were facing a reasonably foreseeable natural death and met an explicit set of eligibility criteria as determined by qualified health care providers (physicians or nurse practitioners). In 2021, the legislation was extended to include the possibility of MAiD for persons who were suffering from a ‘grievous and irremediable’ medical condition but for whom natural death was not immediately foreseeable. As assisted dying represented a significant change in available options for Canadians with terminal or chronic conditions, requiring significant practice adaptations and including numerous legal, social, ethical, moral implications, the health research community has been working in consultation with clinicians, service providers and governments to generate knowledge that ensures safe, ethical and equitable practice in this regard.
Dr. Chunmiao Zheng[/caption]
Chunmiao Zheng, PhD
AGU Fellow, Chair Professor
Hydrologic Science
Eastern Institute of Technology
Ningbo, China
MedicalResearch.com: What is the background for this study?
Response: Per- and polyfluoroalkyl substances (PFAS) are a class of artificially synthesized chemicals widely used in industrial production and consumer goods manufacturing. These substances are persistent in the environment, can accumulate through the food chain, and enter the human body and build up over time, posing a potential threat to health. As an important component of the global diet, marine fish may serve as a major source of PFAS intake for humans. However, the contribution of marine fish as a source of PFAS exposure and the associated health risks still lack systematic assessment on a global scale.
Samson Nivins PhD
Postdoctoral Researcher, specializing in Perinatal and Pediatric Neurology
[caption id="attachment_71834" align="alignleft" width="92"]
Dr. Stone[/caption]
Co-author Meredith Stone, PhD
Assistant Director for Cell Therapy Translation
in Dr. Davila’s lab at Roswell Park - presenting author
MedicalResearch.com: What is the background for this study?
Response: While CD19-targeted CAR T cell therapy has garnered clinical success and FDA approval for the treatment of large B cell lymphoma, approximately half of patients suffer from primary resistance or relapse. Increasing evidence suggests that resistance mechanisms are supported by the tumor microenvironment (TME). Cytokines secreted by CAR T cells can remodel the TME, determining the phenotype and function of other immune cells.
Dr. Bell[/caption]
Dr. Jack Bell
Liverpool Heart and Chest Hospital
Liverpool, UK
MedicalResearch.com: What is the background for this study?
Response: Coronary computed tomography angiography (CCTA) is a non-invasive heart scan used in the first-line investigation of patients with suspected stable coronary artery disease (CAD). While CCTA clearly shows blockages in coronary arteries, it is limited in its ability to estimate reduced blood flow, which is necessary to diagnose angina.
An artificial intelligence-based tool (Heartflow) has been developed that analyses CCTA images and provides an estimate of blood flow: CT-derived fractional flow reserve (FFR-CT). The real-world, retrospective English FISH&CHIPS study demonstrated that including FFR-CT as a decision-making tool in the diagnosis of stable CAD reduces the number of subsequent invasive and non-invasive tests performed.
Whether FFR-CT could also be used prognostically, to predict future major cardiovascular events, was not fully understood. Previous studies have had small patient numbers, short follow-up and investigated combined cardiovascular outcomes. We performed an analysis on the national FISH&CHIPS population, which was large enough to determine if FFR-CT adds incremental value to traditional cardiovascular risk factors in predicting cardiovascular outcomes and death.